SXTP 60 DEGREES PHARMACEUTICALS, INC. Insider Trading

SXTP CEO Geoffrey Dow buys 7,350 shares at $1.38; 5 prior buys at this ticker all showed +97.8% to +2168.8% 90-day returns.

Geoffrey S Dow, President and CEO of 60 Degrees Pharmaceuticals, purchased 7,350 shares at $1.38 on 2026-06-12, increasing his holdings by 43.8% to 24,131 shares. This marks his sixth open-market purchase of SXTP stock. His prior five purchases at this ticker—executed between 2024-12-06 and 2025-12-15—each demonstrated positive 90-day returns ranging from +97.8% to +2168.8%, with 5 of 5 trades well-timed at the 90-day mark. The stock is currently trading at $1.49, down 87.4% from its 52-week high of $11.84, and the company remains unprofitable with net income of $-2.1M against quarterly revenue of $162.1K. The stark contrast between the CEO's historical trade execution at this ticker and the stock's current -87.4% distance from its 52-week high merits direct investor scrutiny of whether these prior 90-day patterns are predictive of market recovery or if the company's fundamental deterioration has invalidated the historical signal.

CEO Geoffrey S. Dow bought 9,670 shares of SXTP at $0.80 on 2025-12-15, extending a pattern of 3 purchases in 5 days as stock trades -92.5% from 52-week high.

Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, purchased 9,670 shares at $0.80 on 2025-12-15, increasing his holdings by 19.4% to 59,618 shares. This represents his third buy in five trading days (prior buys on 2025-12-10 and 2025-12-11 remain unmeasured), following a dramatic 92.5% price decline from the 52-week high of $44.20 to current price of $3.32. Across five prior same-ticker buys spanning late 2024, Dow's timing proved accurate at the 90-day mark (returns of +1614.0%, +2168.8%, and +2345.4%), and his broader cross-ticker track record shows a 100.00% win rate on 90-day returns averaging +2745.4%. The company faces material headwinds: unprofitable on a full-year basis (net loss of $-2,316,324.00 in the latest quarter), with quarterly revenue of only $437,600.00 against a market cap of $14,045,087.36, though annual revenue growth reached +139.6% year-over-year. The rapid sequence of insider buys during steep decline, combined with proven historical timing acuity at this ticker, contrasts sharply against the company's financial distress and the stock's -8.8% drop over 30 days and -42.4% over 90 days.

President/CEO Geoffrey Dow purchases 12,963 shares at $0.94 avg across 2 transactions; stock down 92.3% from 52-week high, yet 5 of 5 prior same-ticker buys well-timed at 90-day horizon.

Geoffrey Dow, President and CEO of 60 Degrees Pharmaceuticals, executed 2 separate purchases totaling 12,963 shares for $12,204.42 on December 10-11, 2025, at a blended average price of $0.94—representing a 35.0% increase to his holdings. This occurs in a severely distressed context: the stock trades at $3.41, having collapsed 92.3% from its 52-week high of $44.20, with a 30-day decline of -30.7%. The company faces fundamental headwinds (unprofitable in its most recent full fiscal year with net income of $-2,316,324.00, though revenue grew 139.6% year-over-year). The most striking signal is Dow's pattern at this same ticker: his prior 5 buys at SXTP all posted positive 90-day returns (ranging from +390.6% to +1,061.8%), with 100% of those purchases well-timed at the 90-day mark. This established track record of accurate timing at this specific stock contrasts sharply with the current distressed valuation and creates substantive investor relevance, though the company's unprofitability and recent sharp price decline warrant deep analysis to establish whether current conditions mirror or diverge from the context of those prior successful trades.

Director Xu Cheryl purchased 5,000 shares at blended $2.88 on 2025-06-03; 5 prior SXTP buys all posted positive 90d returns (range +337.5% to +360.5%).

Xu Cheryl, a Director, executed two separate purchases totaling 5,000 shares for $14,410.00 on 2025-06-03, increasing her holdings by 46.2% from 10,816 to 15,816 shares. This filing is significant because her prior trade history at SXTP shows a striking pattern: all 5 prior buys at this ticker were well-timed, with 90-day returns ranging from +337.5% to +360.5%, and cross-ticker her track record shows a 100.00% 90-day win rate across 9 prior buys with an average 90-day return of +2034.8%. The company currently trades at $11.84, down 85.9% from its 52-week high of $84.24, though it has gained 21.3% in the last 30 days and 89.7% over 90 days. However, fundamentals show SXTP remains deeply unprofitable with a net income of $-1,876,549.00 despite revenue growth of +139.6% year-over-year, and the latest quarter showed only $163,552.00 in revenue against a $17.4M market cap. The insider's historical precision at this ticker contrasts sharply with the company's financial distress, making this purchase's timing and significance material for investors to monitor.

Director Xu Cheryl bought 13,000 shares (13.0K shares) for $21,400.00 ($21.4K) across 7 purchases; holdings rose 31.6%.

Director Xu Cheryl executed 7 separate purchases totaling 13,000 shares for $21,400.00 at prices ranging from $1.45 to $1.85 over three trading days (2024-12-12 through 2024-12-16), raising her holdings from 41,078 shares to 54,078 shares—a 31.6% increase in position size. Her prior two open-market purchases at 60 Degrees Pharmaceuticals delivered exceptional returns (30d +1358.4% and +18581.6%, 90d +1276.5% and +14607.2% respectively), demonstrating a strong track record of well-timed entry points at this ticker. The stock currently trades at $27.60, representing a 90.2% decline from its 52-week high of $283.20, yet the director's recent accumulation below $1.85 reflects accumulation during an extended drawdown; her purchases are occurring at prices substantially below current levels. This multi-leg purchase pattern mirrors her successful prior timing at SXTP and appears consistent with her historically effective entry discipline across the insider's trading history.

SXTP CEO Geoffrey Dow purchased 73,951 shares across 3 transactions (Dec 5-9) for $89,755.18; holdings grew 358.5%, blended price $1.21 vs current $29.00.

Geoffrey Dow, President and CEO of 60 Degrees Pharmaceuticals, made 3 separate open-market purchases totaling 73,951 shares for $89,755.18 between December 5–9, 2024, at prices ranging from $1.11 to $1.27. This acquisition more than quadrupled his holdings from 20,629 to 94,580 shares (+358.5%). The current stock price of $29.00 now stands 89.8% below its 52-week high of $283.20, while showing a 30-day gain of +52.3% from the transaction window. Dow's prior trade at this ticker (January 31, 2024) achieved a 90-day return of +14607.2%, demonstrating historical success timing entries at this stock; his cross-ticker track record spans 4 prior buys with a 100% 90-day win rate and an average 90d return of +14607.2%. However, the company remains unprofitable (full-year net income: $-2,159,785.00) despite recent revenue growth of +13.6%, and the stock's multi-month volatility—trading from $14.44 to $283.20 in the 52-week range—reflects underlying business or market uncertainty that warrants scrutiny of the fundamentals driving this concentrated accumulation.

SXTP CEO Geoffrey Dow bought 7,000 shares across 3 transactions (Nov 19-21) at blended $0.91, raising stake 51.4% to 20.6K shares

Geoffrey Dow, President and CEO, executed 3 separate purchases totaling 7,000 shares for $6,367.45 ($6.4K) at prices between $0.90–$0.92, expanding his holdings by 51.4% from 13.6K to 20.6K shares. The timing is notable given the stock's sharp recent decline: SXTP trades at $17.48 today but stood at $283.20 within the 52-week period, representing a 93.8% drawdown from peak, with a 51.7% decline over the prior 90 days. Dow's prior open-market buy at SXTP on 2024-01-31 posted a 90-day return of +14607.2%, suggesting his earlier trade entry preceded substantial gains. However, the current trading price of $17.48 significantly exceeds the transaction prices of $0.90–$0.92, creating a wide divergence that merits scrutiny: the purchases occurred at extreme lows relative to the company's recent valuation range, yet the stock now trades substantially higher, raising questions about what fundamental or market conditions may have changed. The company reported unprofitable operations (net income of $-2.2M in the latest full year) and minimal recent quarterly revenue ($135.3K), context that underscores the volatility and speculative nature of this micro-cap position.

Director XU CHERYL buys 5,000 shares at $1.70 amid 91.2% drawdown from 52-week high; prior same-ticker buy gained +18581.6% in 90 days

XU CHERYL purchased 5,000 shares at $1.70, expanding her holdings by 13.9% at a price that is -91.2% from the 52-week high of $295.20. The current price of $26.00 reflects a -19.8% decline over 30 days and -61.6% over 90 days, placing this transaction in a severe downtrend. Her prior buy at this same ticker on 2024-01-31 achieved returns of +18581.6% over 90 days, suggesting her timing on SXTP historically has been exceptional. However, the company faces significant headwinds: it is unprofitable (net income of $-4,172,755.00 over the most recent full fiscal year) with minimal quarterly revenue of $124,972.00, though annual revenue growth stands at +13.6%. The stark contrast between her prior 90-day success at this ticker and the current severe valuation decline suggests this transaction warrants close examination of what has changed in the company's fundamentals or market positioning since her last well-timed entry.